Interaction Checker

Wechselwirkungen von Octreotid

Octreotid (Sandostatin, Bynfezia, Mycapssa) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 125 dokumentierte Wechselwirkungen: 0 schwerwiegende, 125 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Mittelschwere Wechselwirkungen (125)

  • AcarboseAntidiabetikumMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • AcebutololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • AlogliptinDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Alogliptin und MetforminDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • AmlodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Amlodipin und AtorvastatinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Amlodipin und BenazeprilDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Antazida (Tums, Maalox, Mylanta)Rezeptfreies PräparatMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • AtenololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • BetaxololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • BexagliflozinSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • BisoprololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Brimonidin und TimololAlpha-Adrenozeptor-AgonistMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • BromocriptinDopaminagonistMittelschwer

    Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • CanagliflozinSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • CarvedilolBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • ChinidinAntiarrhythmikumMittelschwer

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • CiclosporinImmunsuppressivumMittelschwer

    Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • DapagliflozinSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Dapagliflozin und MetforminSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • DexlansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Dextromethorphan und Chinidinserotonerges ArzneimittelMittelschwer

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • DigoxinDigitalisglykosidMittelschwer

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Dorzolamid und TimololCarboanhydrasehemmerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • DulaglutidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • EmpagliflozinSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Empagliflozin und MetforminSGLT-2-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • EsmololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • EsomeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • EstradiolEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Estradiol und Dienogestorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Estradiol und NorethisteronEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Etonogestrel und EthinylestradiolEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Etynodioldiacetat und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • ExenatidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • FamotidinH2-BlockerMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • FelodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • FulvestrantEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • GlibenclamidSulfonylharnstoffMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Glibenclamid und MetforminSulfonylharnstoffMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • GlimepiridSulfonylharnstoffMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • GlipizidSulfonylharnstoffMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Glipizid und MetforminSulfonylharnstoffMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • GlucagonMittelschwer

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Humaninsulin (Normalinsulin)InsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Ibuprofen und FamotidinNSARMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Insulin aspartInsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin degludecInsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin detemirInsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin glarginInsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin lisproInsulinMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • IsradipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Konjugierte EstrogeneEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Konjugierte Estrogene und BazedoxifenEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • LabetalolBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • LansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • LevonorgestrelGestagenMittelschwer

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Levonorgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • LevothyroxinSchilddrüsenhormonMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Levothyroxin und LiothyroninSchilddrüsenhormonMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • LinagliptinDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Linagliptin und MetforminDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • LiothyroninSchilddrüsenhormonMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • LiraglutidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • LisinoprilACE-HemmerMittelschwer

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • MedroxyprogesteronGestagenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • MegestrolGestagenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • MetforminBiguanidMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • MetoprololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • MifepristonCYP3A4-HemmerMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • MiglitolAntidiabetikumMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • NadololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Naproxen und EsomeprazolNSARMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NateglinidGlinidMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • NatriumhydrogencarbonatAntazidumMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NebivololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • NicardipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NifedipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NimodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NisoldipinDihydropyridin-CalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NizatidinH2-BlockerMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Norelgestromin und EthinylestradiolEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • NorethisteronGestagenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Norethisteron und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Norgestimat und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Norgestrel und Ethinylestradiolorales KontrazeptivumMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • OmeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Omeprazol und NatriumhydrogencarbonatProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • PantoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • PindololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • PioglitazonThiazolidindion (Glitazon)Mittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Pioglitazon und MetforminThiazolidindion (Glitazon)Mittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • ProgesteronGestagenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • PropranololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • PropylthiouracilThyreostatikumMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • RabeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • RanitidinH2-BlockerMittelschwer

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • RepaglinidGlinidMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • SaxagliptinDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Saxagliptin und MetforminDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • SemaglutidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • SitagliptinDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Sitagliptin und MetforminDPP-4-HemmerMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • SotalolBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • TelotristatMittelschwer

    Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (Fachinformation zu Telotristat, Arzneimittelwechselwirkungen)

  • TeriparatidSchilddrüsenhormonMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • ThiamazolThyreostatikumMittelschwer

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • TimololBetablockerMittelschwer

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • TirzepatidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • VerapamilCalciumkanalblockerMittelschwer

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Veresterte Estrogene und MethyltestosteronEstrogenMittelschwer

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Fachinformation zu Octreotid, Arzneimittelwechselwirkungen)

  • Vitamin B12Vitamine und MineralstoffeMittelschwer

    Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Octreotid gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.